MTOR and breast cancer: Trial eligibility criteria excluded patients with a history of drug-induced pneumonitis within the prior 12 months, those with a history of pneumonitis related to an mTOR inhibitor, and those with clinically significant pulmonary disease unrelated to breast cancer, thus the enrolled cohort of patients were not at particularly high risk of developing drug-related pneumonitis.